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Abstract
Lentiviral vectors are under intense scrutiny as unique candidate viral vector vaccines against tumor and aggressive
pathogens because of their ability to initiate potent and durable specific immune responses. Strategies that alleviate safety
concerns will facilitate the clinical developments involving lentiviral vectors. In this respect, the development of integration
deficient lentiviral vectors circumvents the safety concerns relative to insertional mutagenesis and might pave the way for
clinical applications in which gene transfer is targeted to non-dividing cells. We thus evaluated the potential use of
nonintegrative lentiviral vectors as vaccination tools since the main targeted cell in vaccination procedures is the non-
dividing dendritic cell (DC). In this study, we demonstrated that a single administration of nonintegrative vectors encoding a
secreted form of the envelope of a virulent strain of West Nile Virus (WNV) induces a robust B cell response. Remarkably,
nonintegrative lentiviral vectors fully protected mice from a challenge with a lethal dose of WNV and a single immunization
was sufficient to induce early and long-lasting protective immunity. Thus, nonintegrative lentiviral vectors might represent a
safe and efficacious vaccination platform for the development of prophylactic vaccines against infectious agents.
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Introduction
Prevention of infectious diseases through vaccine development is
one of the greatest achievements of modern medicine. Nonetheless,
considerable challenges remain for the development of new vaccines
combining efficiencywith enhanced safetyprofiles.Recently,human
immunodeficiency virus (HIV)-1–derived lentiviral vectors have
emerged as very promising vaccination tools. These vectors elicit
both specific cytotoxic and strong humoral immune responses in
several animal models [1,2,3,4,5]. Immune responses elicited by
lentiviral vectors are more efficient than those induced by
conventional viral vector vaccines [6,7,8]. These properties rely in
part on the ability of these vectors to mediate more efficient gene
transfer into dendritic cells (DC) than other vaccinal vectors such as
for instance the widely used adenoviral vectors [9]. This major
advantage allows a sustained expression and endogenous presenta-
tion of tumoral or viral Ags by transduced DC and subsequent
activation of more potent and persistent specific immune responses
[3,10,11,12,13].Moreover,problemsofvector-specificimmunityare
largely reduced with the use of LV because of the absence of pre-
existing immunity in humans.
Although lentiviral vector-based vaccines have been shown to
elicit unparallel specific and protective immunity against tumor
and infectious agents, their transition as vaccinal vectors from
preclinical evaluation to clinical development is hindered by their
status of integration-competent viral vectors and potential
problems linked to the non-specific integration of the transgene
in the genome of the transduced cells. However, several arguments
point out that lentiviral vectors possess a much safer profile than
other retroviral vectors, especially when they are applied to the
field of vaccination. Firstly, in a vaccination scenario based on
direct injection of Ag-encoding lentiviral vectors, transduced cells
that express the relevant Ag become targets of the elicited immune
response and are eliminated within a few weeks from the
vaccinated organism [14]. Secondly, the deletion in the 39 LTR
of the viral promoter and enhancer sequences in self-inactivating
lentiviral vectors limits the likelihood of endogenous promoter
activation [15]. Thirdly, although many lymphocytes of HIV-
infected patients carry a large number of transcriptionally active
HIV integrated proviruses, there is no evidence to suggest that
integration of lentiviruses would cause oncogenesis. Consistently, a
recent study has provided evidences that lentiviral vector
transduction, even at high integration loads do not accelerate
tumorigenesis in a tumor-prone murine model [16]. Nevertheless,
investigations to confirm the safety of lentiviral vectors or
elaboration of novel strategies bypassing these safety consider-
ations need to be actively pursued. In this context, the
development of lentiviral vectors that allows a targeted integration
or does not integrate at all would provide an important step
toward the development of fully safe vector-based vaccines. The
last strategy can be easily achieved with the use of integration-
deficient lentiviral vectors carrying a defective integrase mutated in
residues critical for the integration of viral DNA into the host
genome. One of the most well-studied mutation is the D64V
substitution in the catalytic domain of the enzyme, which has been
shown to block the DNA cleaving and joining reactions of the
integration step [17]. The incorporation of this mutation in
pseudotyped HIV-1 particles or in lentiviral vector particles leads
to only barely detectable integration events and accumulation of
extrachromosomal non-replicating circular genomes in the nucleus
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through cell division but support transcription by the cellular
machinery, allowing stable transgene expression in non-dividing
cells. As such, lentiviral vectors defective for integration could
supersede their integrating counterparts in clinical purposes that
target postmitotic cells. This notion was supported by recent
studies demonstrating the efficiency of nonintegrative lentiviral
vectors to transduce primary cells such as neuronal cells [19],
muscle cells [20] or retinal cells and to rescue representative
models of retinal degeneration [21].
In this study, we asked whether integration-deficient lentiviral
vectors could initiate a specific and protective immune response.
We hypothesized that the induction of Ag specific immune
responses in vaccine strategies with lentiviral vectors should not
require vector integration, since targeted cells are non-dividing
DC. To test this hypothesis, we firstly evaluated the ability of these
vectors to transduce in vitro different subpopulations of DC. We
next investigated whether immunization with nonintegrative
lentiviral vector particles was efficient to stimulate a specific and
protective humoral immune response against West Nile Virus
(WNV), a flavivirus responsible for the largest recognized epidemic
of neuroinvasive human disease in North America.
We show that integration-deficient lentiviral particles are not
only efficient in transducing DC but also that a single
immunization with these vectors coding for the secreted form of
the WNV envelope can prime humoral Ag-specific responses and
confers complete protection against lethal challenge.
Results
Transduction of non-dividing cells with lentiviral vectors
deficient for integration results in high transgene
expression levels
To test the hypothesis that integration deficient lentiviral vectors
could be efficient tools to deliver Ags to non-dividing antigen-
presenting cells such as DC, we initially evaluated their transduction
efficiency in growth-arrested cells. For this purpose, HeLa cells
treatedwithaphidicolin,aspecificinhibitorofcellcycle,wereexposed
to increasing doses of nonintegrative or integrative lentiviral vectors
encoding eGFP and transduction efficiency was determined by flow
cytometry. It is important to note that, as previously described [21],
the titers of integrative and nonintegrative lentiviral vectors were
similar according to p24 content and quantitative PCR titration as
described in Material and Methods. A similar expression kinetics
experiments in dividing HeLa cells using the integrase defective
(D64V) vector, led to progressive loss of GFP transgene expression to
undetectable levels, as previously described [20,21], confirming the
non integrated status of the vector genome (data not shown).
As shown in Figure 1A, integration-deficient lentiviral vectors
transduced non-dividing cells with high efficiency and in a dose
dependent manner. Moreover, analysis of the percentage of eGFP
positive cells revealed marginal differences in the capacities of
transduction of integration-deficient vectors compared with
integration-proficient vectors. Transduction with nonintegrative
vectors yielded also high levels of expression of the transgene
(Fig. 1B), although significantly lower by a 2-fold factor compared
to integrative lentiviral vectors.
Nonintegrative lentiviral vector transduction leads to
effective antigen expression both in conventional and in
plasmacytoid dendritic cells
We next studied the ability of integration-deficient lentiviral
vectors to transduce DC. Murine DC are categorized into
conventional (cDC) (CD11c
+ B220
2) and plasmacytoid (pDC)
(CD11c
+ B220
+) and both these DC subtypes are able to stimulate
Ag-specific immune responses [22]. We then investigated the
transduction of bone marrow-derived DC differentiated in
presence of Flt3L (FL-DC), which allows the generation of large
numbers of pDC and cDC. FL-DC were exposed to increasing
doses of integration-deficient or –proficient eGFP-encoding
vectors. As shown in Figure 2A, both integrative and noninte-
grative lentiviral vectors were capable of transducing FL-DC with
maximal transduction of efficiency of 60% and 56% respectively.
Interestingly, we observed that transduction with integrative
vectors led to a small proportion of DC expressing high levels of
eGFP, whereas transduction experiments with nonintegrative
vectors did not (Blue gates, 1.4% with TRIP.I eGFP and 0.1%
with TRIP.NI eGFP). To rule out the possibility of pseudo-
transduction conferred by residual eGFP proteins included in the
particles, we also evaluated the percentage of transduced DC after
exposure to particles submitted prior to a heat-treatment, which
has been shown to abrogate the transduction capabilities of
lentiviral vectors on different cell types. As expected, the heat-
treatment decreased drastically the percentage of eGFP positive
cells. The same level of reduction was also observed in growth-
arrested cells transduced with nonintegrative lentiviral vectors in
the presence of Nevirapin, a specific inhibitor of the reverse
transcriptase (data not shown). Thus, the GFP fluorescence
Figure 1. Efficient transduction of non-dividing cells with
lentiviral vectors defective for integration. Aphidicolin-treated
HeLa cells were transduced with graded doses (1–100 ng of p24
antigen) of eGFP-integrative vectors (TRIP.I eGFP) or eGFP-nonintegra-
tive vectors (TRIP.NI eGFP). FACS analysis of the percentage of GFP
positive cells (A) and the MFI (B) at 48 hours post-transduction is
shown.
doi:10.1371/journal.pone.0003973.g001
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from pseudotransduction ofencapsidated GFP proteins.
We next gated on CD11c
+ B220
+ and CD11c
+ B220
2 to
evaluate the capacity of lentiviral vectors to transduce each DC
subset. As shown in Fig. 2B, not only FL-derived cDC but also FL-
derived pDC could be efficiently transduced with lentiviral vectors,
regardless of their integration proficiencies. Thus, efficient
transduction can be achieved in different subpopulations of DC
with integration-deficient lentiviral vectors, although levels of
expression of the transgene are lower compared to integrative
vectors-transduced cells.
Nonintegrative lentiviral vectors induce the production
of Ag-specific antibodies
Taking into account that integration-deficient lentiviral vectors
could allow efficient expression of a foreign gene in professional
antigen-presenting cells, we next explored their abilities to mount a
specific immune response. In a recent study, we have designed
integrative lentiviral vectors coding for a secreted form of WNV
envelope (EWNV) which possesses neutralizing epitopes and we
have demonstrated that these vectors could stimulate a massive
production of anti-WNV antibodies [4]. To investigate the ability
of nonintegrative lentiviral vectors to initiate a B cell response and
to compare the strength of the immune response elicited by
lentiviral vectors defective or not for integration, groups of C57/
Bl6 mice (n=6) were immunized with various doses of integrative
or nonintegrative vectors coding for EWNV ranging from 1 to
100 ng of p24 antigen per mouse (corresponding to 1610
5 to
1610
7 transduction units). As a control, mice were inoculated with
100 ng of nonintegrative EWNV vector particles inactivated by
heating to abrogate their transduction capacities. Three weeks
after immunization, pooled sera collected from each group of
immunized mice were tested for the presence of total anti-WNV
antibodies. As expected, immunizations with 100 ng of heat-
inactivated lentiviral vectors (HI 100) were not followed by the
production of antibodies (Fig. 3). By contrast, mice immunized
with a dose as low as 10 ng of nonintegrative EWNV vectors
displayed detectable levels of anti-WNV antibodies and immuni-
zations with 100 ng of this vector induced a massive secretion of
anti-WNV Ig with a mean titer reaching 8610
4. As shown in
Fig. 3, integrative lentiviral vectors elicited a higher immune
response than nonintegrative vectors at doses below 30 ng, but
vaccinations with 100 ng of either vector led to an equivalent
intense humoral immune response.
Taken together, these results demonstrated that a single
immunization with nonintegrative lentiviral vectors was sufficient
to elicit a humoral specific immune response with a strength
comparable to that obtained with integrative vectors, above a
threshold dose of particles.
Immunization with nonintegrative lentiviral vectors
confers early protection against WNV challenge
We have previously shown that integrative lentiviral vectors
conferred an early protective immunity against a WNV challenge,
a critical feature in the context of a WNV outbreak. To determine
if the immune response elicited by integration-deficient lentiviral
vectors could also lead to a rapid protection, mice were
immunized with 100 ng of nonintegrative EWNV vector particles
and challenged 7 days later with 10,000 FFU of the highly virulent
WNV strain IS-98-ST1 (one thousand times the dose required to
kill 50% of infected animals). We also included in this challenge
experiment a group of mice immunized with 100 ng of integrative
EWNV lentiviral vectors as a positive control of protection and
another group of mice inoculated with D-PBS as a negative
control. As expected, all mice that received D-PBS died within 12
days post-challenge (Fig. 4). In contrast, all mice immunized with a
single dose of nonintegrative EWNV lentiviral vectors were
protected from the challenge, as were mice immunized with
integrative vectors. Moreover, mice protected from WNV
Figure 2. Lentiviral vector transduction leads to effective
antigen expression both in conventional dendritic cells (cDC)
and in plasmacytoid DC (pDC). (A) Dose-response transduction
experiments with eGFP-integrative vectors (TRIP.I eGFP) or eGFP-non
integrative vectors (TRIP.NI eGFP), heat-inactivated (HI) or not. On day 6
of differentiation, FL-DC were exposed to vector particles for 48 hours
and transduction of CD11c positive cells was assessed by measuring
eGFP expression by flow cytometry. Numbers indicate the percentage
of CD11c
+ cells expressing eGFP. Blue gates delineate a DC population
expressing high levels of eGFP. (B) Transduction of pDC and cDC by
lentiviral vectors. Expression of eGFP by cDC (CD11c
+ B220
2) and pDC
(CD11c
+ B220
+) is shown. Thin lines, control cells; filled profiles, FL-DC
transduced with 300 ng/ml of vector particles.
doi:10.1371/journal.pone.0003973.g002
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weeks post-challenge observation period. These results demon-
strated that an early protective immunity against WNV was
achieved with a single administration of lentiviral vector defective
for integration.
Nonintegrative lentiviral vector immunization induces
long-lasting protection
As demonstrated earlier, immunization of mice with integrative
lentiviral vectors coding for EWNV resulted in the establishment of
long-term protective immunity against WNV challenge [4]. To
evaluate the duration of the protective immunity elicited by
nonintegrative EWNV lentiviral vectors and the minimum dose of
particles required to induce long-term protection, mice were
immunized with different amounts of particles (1, 3, 10, 30 and
100 ng of p24 antigen) and were challenged 2-months post-
immunization. As shown in Figure 5, there was a dose-dependent
relationship between the quantity of nonintegrative EWNV vector
particles administrated and the degree of protection, with a full
protection achieved at a dose of 100 ng of vaccine particles
injected. In contrast, a 100% protection was achieved after a single
injection of integrative EWNV vector particles regardless the dose.
Thus, long-lasting immunity against WNV infection can be
achieved with a nonintegrative lentiviral vector-based vaccine.
Discussion
We have demonstrated for the first time that safe nonintegrative
lentiviral vectors are not only effective at transducing different
subpopulations of DC but also that a single immunization with
these vectors was sufficient to afford complete protective immunity
against a lethal viral challenge in mice. Transduction efficiency of
both plasmacytoid and conventional DC with nonintegrative viral
particles was dose dependent and led to the same levels of
transduction than those obtained with integrative particles.
Although transduction of both growth-arrested cells and DC with
nonintegrative lentiviral vectors led to high levels of expression of
the transgene, the levels were approximatively 2 fold lower than
that achieved with integrative lentiviral vectors.
Immunizations of mice with a single dose of 100 ng of
nonintegrative lentiviral vectors coding for a secreted form of
the envelope of WNV induced an equivalent level of specific WNV
antibodies to that obtained with the same dose of integrative
vectors with a mean titer reaching 8610
4. However, dose-response
experiments revealed that the minimal dose required for the
induction of a B cell response was lower with TRIP.I particles
compared to the TRIP.NI particles. One possible explanation for
this result could be related to the ability of integrative lentiviral
vectors to generate a more sustained production of Ag in
transduced DC since, theoretically, high expression levels of the
Ag in the DC could favor a more sustained presentation of
antigenic peptides and may thus explain why low doses of
integrative vector particles were sufficient to elicit a specific
immune response. An alternative or complementary explanation is
that VSV-G pseudotyped particles have a large cellular tropism
and thus, may transduce at the site of injection other cell types
than DC, including dividing cells. This could result in a more
sustained expression of the Ag in vaccination experiments with
integrative vector particles. Which cell types are transduced after
in vivo injections of lentiviral vector particles and to what extend
they are involved in the magnitude of the immune response
elicited by integrative and nonintegrative lentiviral vectors is the
subject of ongoing research.
Figure 3. A single dose of nonintegrative lentiviral vector
coding for EWNV elicits a strong and specific antibody
response. Groups of adult mice (n=6) were immunized intraperito-
neally with graded doses (1–100 ng of p24 antigen) of TRIP.NI EWNV or
TRIP.I EWNV particles. Control mice were inoculated with 100 ng of heat-
inactivated (HI) particles. After 21days, pooled sera (6 mice per group)
were assessed for the presence of WNV-specific antibodies. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0003973.g003
Figure 4. Rapid protection against WNV infection conferred by
nonintegrative lentiviral vector immunization. Six mice/group
were vaccinated with 100 ng of TRIP.NI EWNV or 100 ng of TRIP.I EWNV.A
control group of mice inoculated with phosphate-buffered saline (PBS)
was included. One week after the vaccination, mice were challenged
with 1,000 i.p. LD50s of WNV strain IS-98-ST1. Survival was recorded for
21 days. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0003973.g004
Figure 5. Efficient long-term protection against WNV infection
by nonintegrative lentiviral vector-based vaccine. Two months
post-immunization with graded doses (1–100 ng of p24 antigen) of
TRIP.NI EWNV or TRIP.I EWNV particles, groups of mice (6 mice per group)
were inoculated with 1,000 i.p. LD50s of WNV strain IS-98-ST1. Survival
was recorded for 21 days. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0003973.g005
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vaccination with a single dose of 100 ng of nonintegrative EWNV
particles was sufficient to elicit a very early, long-lasting and fully
protective immunity against a challenge with a lethal dose of
WNV. Kinetic challenge experiments on vaccinated mice revealed
that nonintegrative vector-based vaccines conferred a protective
immunity as early as one week after a single injection of particles.
Although the exact mechanisms involved in this early protection
are not fully understood, we have detected specific WNV
antibodies one week after immunizations with nonintegrative
and integrative vector particles (data not shown). We have
previously shown that this early wave of antibodies were
exclusively composed of specific IgM, which have been shown to
completely protect mice against WNV infection [4,23]. Intrigu-
ingly, low doses (1 and 3 ng of particles) of nonintegrative lentiviral
vectors were able to confer a partial long-lasting protective
immunity against WNV challenge (Fig. 5), although no WNV-
antibodies were detected in the sera of animals 3 weeks after
injection (Fig. 3). Even if it is widely accepted that the humoral
immune response is an essential component of protective
immunity, these unexpected results suggest that cellular immunity
could also play a partial role in the establishment of protection
against WNV. Consistent with this hypothesis, two recent studies
have identified CTL epitopes in the envelope and CTL directed
against these epitopes conferred partial protection against WNV
challenge. Whether a T cell response could be mounted by
nonintegrative lentiviral vectors and could contribute to protection
against WNV challenge remains to be determined. However, data
obtained by us and others [24] in another model of antigenic
vaccination support the concept that nonintegrative lentiviral
vectors can also prime CD8+ T cells.
Until now, potential applications of lentiviral vectors in the field of
vaccinology were mainly restricted to therapeutic interventions
against fatal diseases such as advanced cancers [25]. Lentiviral
vectors deficient for integration offer great potential for therapeutic
vaccination but the demonstration that they can elicit effective
protectiveimmunityopensalsoforthefirsttimethepossibilityofusing
lentiviral vectorsinlarge-scaleprophylactic vaccinations.Indeed, this
new generation of lentiviral vector-based vaccines alleviates concerns
of potential problems associated with non specific integration of a
transgenesinceresidualintegrationeventswiththeselentiviralvectors
mutants has been shown to be barely detectable and are due to non-
homologousrecombinationevents[18].Theserareintegrationevents
may also occur with other transient gene delivery methods, such as
adenoviral vectors or nonviral plasmid-based vaccines. Moreover,
nonintegrativelentiviral vectors preserve many favourablefeatures of
conventional integrative lentiviral vectors, including vector stability,
high production yields and infectivity. Finally, a single injection of
nonintegrative lentiviral vectors can be sufficient to induce a fully
protective immunity against pathogens, as illustrated in our study.
This represents a major advantage in terms of cost-effectiveness,
allowing mass vaccination even in developing countries.
Even if further works are needed to explore the efficacy of
nonintegrative lentiviral vectors especially in the field of specific
cellular immune responses, we envision that nonintegrative- based
vaccine strategy could represent a very promising platform for the
development of vaccines with fewer safety concerns and potent
protection immunity.
Materials and Methods
Cell culture and virus preparations
Hela cells, Human 293T cells and African green monkey kidney
Vero cells were cultured in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% (Hela cells, 293T cells) or 5%
(Vero cells) heat-inactivated fetal calf serum (FCS), penicillin,
streptomycin and Glutamax (GIBCO). WNV strain IS-98-ST1
(GenBank accession number AF 481 864) [26], a closely related
variant of NY99 strain [27,28,29], was propagated in mosquito
Aedes pseudoscutellaris AP61 cell monolayers. Purification in sucrose
gradients and virus titration on AP61 cells by focus immunodetec-
tion assay using anti-WNV hyperimmune mouse ascitic fluid were
performed as previously described [30,26,31]. Infectivity titers
were expressed as focus forming units (FFU).
Lentiviral vector production
The TRIP EWNV and TRIP GFP vector plasmids were
constructed as previously described [4]. Vector particles were
produced by transient calcium phosphate co-transfection of 293T
cells with the vector plasmid pTRIP/sEwnv, a VSV-G envelope
expression plasmid (pHCMV-G) and an encapsidation plasmid
(p8.74 or pD64V for the production of integration-proficient or
integration-deficient vectors respectively) as previously described
[32]. Quantification of the p24 antigen content of concentrated
vector particles was performed with a commercial HIV-1 p24
enzyme-linked immunosorbent assay (ELISA) kit (Perkin Elemer
Life Sciences). Vector titers of TRIP.I and TRIP.NI particles were
determined by transducing HeLa cells treated with aphidicolin
and performing a quantitative PCR as previously described [4].
The titers of integrative and nonintegrative lentiviral vectors were
similar according to p24 content and quantitative PCR measured
in growth-arrested cells.
Preparation of bone marrow-derived dendritic cells
Bone marrow cells were isolated by flushing femurs and tibiae
with RPMI supplemented with 10% FCS. Cells were then passed
through a 45-mm cell strainer, centrifuged and resuspended in IO
Test 3 lysing solution (Beckman Coulter) and incubated at 4uC for
5 min to lyze red blood cells. The cells were centrifuged and
cultured for 8 days at 1610
6 cells/ml in culture medium consisting
of RPMI with 10% FCS, L-glutamine, penicillin, streptomycin,
1 mM sodium pyruvate, 10 mM HEPES, and 50 mM2 -
mercaptoethanol supplemented with 100 ng/ml of recombinant
mouse FLT3 ligand (R&D Systems).
Transduction experiments and flow cytometry analysis
For transduction experiments on non-dividing cells, Hela cells
were seeded in 48 wells plates at 40,000 cells/well in the presence
of 8 mM of aphidicolin (Sigma). Cells were transduced 24 hours
after the aphidicolin block, which was replenished in the medium
at the time of transduction. At 2 days post-transduction, cells were
harvested and eGFP expression was analyzed by flow cytometry.
For DC transduction experiments, FLT3L-generated-bone mar-
row-derived DC (FL-DC) were transduced at day 6 of the
differentiation. At 2 days post-transduction, FL-DC were harvest-
ed and resuspended in PBS with 2% FCS and 0.01% sodium azide
(staining buffer). Cells were stained with an APC-conjugated anti-
CD11c antibody (BD biosciences) and a PerCP-conjugated anti-
B220 antibody (BD biosciences), washed twice and analyzed by
flow cytometry on a FACSCalibur (BD biosciences, Franklin
Lakes, NJ).
Mice immunization and WNV challenge
All animal experiments were conducted in accordance with the
guidelines of the Office Laboratory of Animal Care at the Pasteur
Institute. Six-week-old C57/Bl6 mice were intraperitoneally (i.p.)
inoculated with varying doses of TRIP.EWNV vector particles in
Lentiviral Vector Vaccine
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supplemented with buffered 0.2% bovine serum albumin
(DPBS/0.2% BSA, Sigma). WNV challenge was performed by
i.p. inoculation of neurovirulent WNV strain IS-98-ST1 (i.p. LD
50=10 focus-forming units (FFU)) as previously described [30,
26]. The challenged mice were monitored daily for signs of
morbidity or mortality, for up to 21 days.
Measurement of serum antibody responses
Mice were bled via the periorbital route and serum samples
were heat-inactivated 30 min at 56uC. Anti-WNV antibodies were
detected by ELISA, by use of microtitration plates coated with
sucrose-purified WNV IS-98-ST1. Peroxydase goat anti-mouse
immunoglobulin (H+L) (Jackson Immuno Research) was used at a
1:4,000 dilution as secondary antibodies. The endpoint titer was
calculated as the reciprocal of the last dilution eliciting twice the
optical density of sera from nonimmunized mice.
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